Can liquid biopsy proteomics revolutionize clinical trial design and drug development? Early phases as a prespecified substudy, late phases not yet

Retinal drug development depends on visual acuity and imaging endpoints that are slow to change and say little about mechanism. Proteomic analysis of ocular fluid, often called liquid biopsy, can now measure thousands of proteins in a few microliters of aqueous humor and infer, through integration with single-cell transcriptomic atlases, the retinal cell types from which many of them are likely to originate. Whether this capability should change how trials are designed is contested. This Perspective sets out both sides of a debate first held at the 16th Congress on Controversies in Ophthalmology. The case for holds that liquid biopsy proteomics can stratify patients by molecular state, show that a drug reaches the eye and shifts its pathway, and support earlier development decisions. The case for caution holds that no ocular fluid biomarker has been validated against clinical outcome, that the published human evidence is small and exploratory, and that sampling, cost and scale limit its use in large trials. We agree on a phase-dependent position: ocular fluid proteomics is promising as a prespecified exploratory or pharmacodynamic substudy in selected phase 0 to 2 trials where the mechanism can be read in fluid; it belongs in a prespecified substudy, not the primary analysis, in phase 3 and 4; and no surrogate endpoint claim should be made until prospective validation exists. We list the studies that would settle the question.

Authors

Institutions

Publication Details

Journal
Frontiers in Ophthalmology
Published
2026-11-20
DOI
https://doi.org/10.3389/fopht.2026.2019091
Primary Topic
Retinal Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Can liquid biopsy proteomics revolutionize clinical trial design and drug development? Early phases as a prespecified substudy, late phases not yet

Vinit B. Mahajan, Anat Loewenstein, David R.P. Almeida
Frontiers in Ophthalmology
Retinal Diseases and Treatments
article

Can liquid biopsy proteomics revolutionize clinical trial design and drug development? Early phases as a prespecified substudy, late phases not yet

Vinit B. Mahajan, Anat Loewenstein, David R.P. Almeida
article en

Abstract

Retinal drug development depends on visual acuity and imaging endpoints that are slow to change and say little about mechanism. Proteomic analysis of ocular fluid, often called liquid biopsy, can now measure thousands of proteins in a few microliters of aqueous humor and infer, through integration with single-cell transcriptomic atlases, the retinal cell types from which many of them are likely to originate. Whether this capability should change how trials are designed is contested. This Perspective sets out both sides of a debate first held at the 16th Congress on Controversies in Ophthalmology. The case for holds that liquid biopsy proteomics can stratify patients by molecular state, show that a drug reaches the eye and shifts its pathway, and support earlier development decisions. The case for caution holds that no ocular fluid biomarker has been validated against clinical outcome, that the published human evidence is small and exploratory, and that sampling, cost and scale limit its use in large trials. We agree on a phase-dependent position: ocular fluid proteomics is promising as a prespecified exploratory or pharmacodynamic substudy in selected phase 0 to 2 trials where the mechanism can be read in fluid; it belongs in a prespecified substudy, not the primary analysis, in phase 3 and 4; and no surrogate endpoint claim should be made until prospective validation exists. We list the studies that would settle the question.

Frontiers in OphthalmologyVol. 6
Tel Aviv Sourasky Medical Center (IL), Stanford University (US)
Good health and well-being
Retinal Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon